- Market Capitalization, $K 2,171,977
- Shares Outstanding, K 161,967
- Annual Sales, $ 389,520 K
- Annual Income, $ 106,180 K
- 60-Month Beta 1.39
- Price/Sales 5.45
- Price/Cash Flow 16.03
- Price/Book 19.21
|Period||Period Low||Period High||Performance|
| || |
+0.44 (+3.46%)since 06/29/21
| || |
+1.90 (+16.87%)since 04/29/21
| || |
+4.02 (+43.98%)since 07/29/20
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.
Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 5, 2021. Individuals...
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
|3rd Resistance Point||14.07|
|2nd Resistance Point||13.86|
|1st Resistance Point||13.51|
|1st Support Level||12.95|
|2nd Support Level||12.74|
|3rd Support Level||12.39|